Topic Editors

Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
Dr. Simon Chu
Hudson Institute of Medical Research and the Monash, University Department of Molecular and Translational Science, Clayton, VIC 3168, Australia
Department of Cell Metabolism and Nutrition, Advanced Preventive Medical Sciences Research Center, Kanazawa University, Kanazawa, Japan

Research Progress of Gynecological Tumor Immunotherapy

Abstract submission deadline
closed (15 March 2023)
Manuscript submission deadline
closed (15 May 2023)
Viewed by
1513

Topic Information

Dear Colleagues,

Gynecologic malignancies include cervical cancer, uterine cancer, ovarian cancer, vaginal cancer, and vulvar cancer, which have a poor prognosis in advanced or recurrent cases, and new treatment strategies are strongly needed. Immune therapy including, but not limited to, the immune checkpoint inhibitors, adoptive cell transfer, therapeutic vaccines, and cytokine treatment, have provided many clinical responses against a wide range of tumor types. As for gynecological cancers, cervical cancer is closely linked to the persistent infection of carcinogenic HPV, which express viral oncogenes, causing the enhancement of genomic instability. Endometrial cancer is the most common with abnormalities in the DNA mismatch repair gene. These genetic abnormalities cause frequent mutations in many genes, resulting in the production of neoantigens. Since some types of gynecological cancers are considered to be highly immunogenic, immunotherapy is expected to be highly effective. Another pressing need is that despite the large number of mutations observed in different types of gynecological carcinomas, only a few mutations can be targeted for therapy. New methods to screen a bulk of mutated genes and accurately link them to highly effective immunotherapies could be a promising breakthrough in gynecologic cancers. This Special Issue welcomes manuscripts addressing any studies involving immunotherapy research in gynecological cancers. We are excitedly inviting you and your colleagues to submit your works regarding immunotherapies for gynecological cancers in all their diversity, covering both basic and (pre-)clinical aspects; comprehensive reviews outlining an overview of the currently available knowledge; and novel findings advancing our knowledge to improve the treatment of gynecologic cancers.

Dr. Takashi Iwata
Dr. Simon Chu
Dr. Guanliang Chen
Topic Editors

Keywords

  • gynecological cancers
  • immunotherapy
  • immune checkpoint inhibitors
  • adoptive cell transfer
  • therapeutic vaccines
  • cytokine treatment

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biology
biology
4.2 4.0 2012 18.7 Days CHF 2700
Cancers
cancers
5.2 7.4 2009 17.9 Days CHF 2900
Cells
cells
6.0 9.0 2012 16.6 Days CHF 2700
Current Oncology
curroncol
2.6 2.6 1994 18 Days CHF 2200
Immuno
immuno
- - 2021 20.7 Days CHF 1000
Vaccines
vaccines
7.8 7.0 2013 19.2 Days CHF 2700

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers

There is no accepted submissions to this Topic at this moment.
Back to TopTop